News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Pulls Bid To Extend Use Of Kidney Drug To Ovarian Cancer


3/31/2014 7:50:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlaxoSmithKline on Monday withdrew an application to use Votrient, a drug licensed for kidney cancer, to treat advanced ovarian cancer after analysis of data from a late-stage trial did not support the benefit-to-risk ratio. The British company said it was disappointed by the findings of the further analysis, which came after it found the drug caused an improvement in progression-free survival in its Phase III study. GSK, which had applied for approval in Europe, said it would also not continue to develop the drug for advanced ovarian cancer in other countries.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at News Release
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES